S

Sanofi

Global pharma company; vaccines and R&D

Third Party Audits Manager - M&S Quality Services

Full-TimeUpdated on 10/24/2026Deadline 10/31/26
No salary listed
Expert
Bachelor's
Petaling Jaya, Selangor, Malaysia
In PersonThe description lists Kuala Lumpur as the role location; ATS workplace scope is Petaling Jaya, Malaysia.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Experience in quality auditing within pharmaceutical, biotech, or regulated manufacturing environments, including hands-on exposure to GxP or cGMP audits of Third Party Manufacturers or Contract Manufacturing Organizations.
  • Strong knowledge of FDA, EMA, and applicable regional health authority regulatory frameworks and the ability to translate them into practical compliance assessments.
  • Ability to plan, conduct, and report on-site or remote audits, identify quality gaps, and drive Root Cause Analysis and Corrective and Preventive Action follow-up to closure.
  • Ability to use quality tools and systems to resolve complex compliance issues and propose process improvements.
  • Ability to manage multiple audits, priorities, and stakeholders simultaneously and adapt plans based on workload and inspection readiness needs.
  • A degree in a scientific, engineering, pharmaceutical, or related quality discipline is expected.
  • Fluency in English is required.
Responsibilities
  • Organize, plan, and perform quality audits of third parties upon request, in accordance with the annual audit program.
  • Provide an independent assessment of third-party quality regarding material compliance and regulatory and quality requirements.
  • Identify gaps and areas for improvement, communicate results as needed, and ensure Corrective and Preventive Actions are available for complete communication.
  • Interface between third parties and the sites using them to facilitate follow-up of improvements and exchange of quality information.
  • Participate in qualifying new auditors in the hub by performing audits with them and providing expertise regarding quality assessment of third parties.
  • Support audits led by other auditors when specific expertise is needed, including for-cause audits with user-site representatives and audits involving highly sophisticated topics.
  • Interact with Global Quality Third Parties Audit Management and Third Parties Quality Management colleagues to support enhancements as required.
  • Propose innovative solutions to improve the Third Parties Quality Audit process as required.
  • Participate in quality documentation updates as required.
  • Provide quality assurance and technical support to Third Party Manufacturers, Contract Manufacturing Organizations, their operations, affiliates, and other stakeholders.
  • Ensure compliance with corporate and divisional quality assurance policies, procedures, standards, and specifications, as well as country-specific regulations applicable to third-party and contract manufacturing locations and markets.
  • Ensure compliance with corporate and divisional quality assurance requirements and identify or resolve quality gaps and issues relating to product design, manufacturing quality programs, and product start-ups at third-party manufacturers and contract manufacturing organizations.
  • Support Root Cause Analysis investigations of quality events as required.
  • Use knowledge of quality assurance systems and problem-solving tools to provide alternative solutions to quality issues.
  • Lead the Quality Compliance team to ensure current Good Manufacturing Practice compliance and inspection readiness.
  • Manage supplier audit programs and follow up on regulatory audits.
  • Oversee regulatory intelligence and contribute to on-site Quality Risk Management.
  • Identify and propose process and procedure improvements.
  • Manage supplier audits, ensuring current Good Manufacturing Practice and standard operating procedure alignment.
  • Track market developments and regulatory changes.
  • Contribute to team effectiveness, identify risks, and formulate improvements.
  • Manage work processes efficiently and comply with applicable laws.
  • Follow up on Corrective and Preventive Actions.
  • Monitor FDA and EMA requirements proactively and share knowledge.
  • Coach and direct the team, conduct evaluation interviews, and assess training needs.
  • Provide an assessment of supplier quality regarding material compliance and regulatory Corrective and Preventive Action for third-party sites.
  • Act as a local quality contact between suppliers, Global Quality Suppliers, and IA sites to facilitate the exchange of quality information.
  • Organize the day-to-day agenda according to the workload defined by the group and establish monthly reports and indicators to support prioritization decisions.
  • Conduct on-site and remote audits of GxP and health-regulated third-party vendors to ensure compliance with regulations and company policies.
  • Prioritize audit planning to meet audit, assessment, and monitoring plans.
  • Collaborate with regional stakeholders on inspection preparedness.
Desired Qualifications
  • Proficiency in Mandarin or Japanese is a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...